A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

This study tests different combinations of three drugs (HLX10, HLX04, and HLX53 — a PD-1 inhibitor, a VEGF inhibitor, and another targeted therapy) as first-line treatment for people with advanced liver cancer (hepatocellular carcinoma) to find the best dosing and evaluate how well they work together. **You may be eligible if...** - You are 18 or older and have been diagnosed with liver cancer (HCC) - You have not previously received any systemic (whole-body) treatment for liver cancer - Your liver cancer is advanced-stage (BCLC stage C, or stage B that cannot be treated with local procedures) - You have at least one tumor that can be measured on imaging - Your liver function is adequate **You may NOT be eligible if...** - You have already received systemic treatment for liver cancer - Your liver function is too poor - You have active hepatitis with uncontrolled viral replication - You have serious autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.